Kivu Bioscience Inc. has released new preclinical efficacy and safety data on KIVU-107, a novel PTK7-targeting antibody-drug conjugate with a DAR4 exatecan payload. KIVU-107 is designed to be highly stable in circulation with negligible free payload release, maximizing on-tumor activity while minimizing off-target toxicity.